Featured Article

Ken Getz of Tufts CSDD and Steve Young of CluePoints Discuss Stand Out Results from Recent RBQM Study

In part 2 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints highlight what stood out to them from the results of a recent study on RBQM adoption.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Blog
From Fragmentation to a Scalable RBQM Operating Model
  • Why tools alone aren’t enough, and what CROs need instead. Most CROs don’t lack RBQM capability....
Read More
Blog
Monitoring Isn’t a Cost Problem. It’s a Margin Lever.
  • Why CROs need to rethink monitoring, not reduce it. For years, the conversation around monitoring has...
Read More
Blog
Why RBQM Fails at Scale in CROs
  • Most CROs don’t lack RBQM capabilities. They lack a model to execute it consistently. Most CROs...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI